The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

(2019) Lea C. Berkhout et al.   Science Translational Medicine

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up

(2018) E. H. Vogelzang et al.   PLoS One

Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis

(2017) E Berthold et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis

(2016) Robin Kahn et al.   ACTA PAEDIATRICA

Mechanism of action of methotrexate in rheumatoid arthritis and the search for biomarkers

(2016) Philip M. Brown et al.   Nature Reviews Rheumatology

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

(2015) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-αand Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

(2014) Martin Schulz et al.   Biomed Research International

Reply to Ruiz-Argüello et al.: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels

(2013) Theo Rispens et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display

(2012) Christian Votsmeier et al.   mAbs

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES